Shanghai Hengrui Pharmaceutical Co., Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
Subsidiary
Established
2001-12-04
Employees
-
Market Cap
-
Website
http://www.shhrp.com
Clinical Trials
Related News

A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

Phase 1
Conditions
B Cell Lymphoma
Interventions
Drug: SHR-A1912
First Posted Date
2021-11-09
Last Posted Date
2023-12-06
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
170
Registration Number
NCT05113069
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children

First Posted Date
2021-11-08
Last Posted Date
2022-11-07
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
159
Registration Number
NCT05111431
Locations
🇨🇳

Beijing Children's Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

A Study of HRS2543 in Patients With Advanced Tumors

Phase 1
Terminated
Conditions
Advanced Tumors
Interventions
Drug: HRS2543
First Posted Date
2021-10-06
Last Posted Date
2024-07-18
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
10
Registration Number
NCT05068856
Locations
🇨🇳

Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, Shanghai, China

A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

First Posted Date
2021-08-06
Last Posted Date
2021-11-16
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
90
Registration Number
NCT04993430
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
Drug: SHR-1707
First Posted Date
2021-07-22
Last Posted Date
2023-05-18
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
63
Registration Number
NCT04973189
Locations
🇨🇳

The second Hospital of Anhui Medical University, Hefei, Anhui, China

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Phase 1
Conditions
Advanced Pancreatic Cancer
Interventions
Drug: SHR-A1904
First Posted Date
2021-06-16
Last Posted Date
2021-08-24
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
75
Registration Number
NCT04928625
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: SHR-1905/placebo
First Posted Date
2021-05-27
Last Posted Date
2024-10-30
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
86
Registration Number
NCT04905602
Locations
🇨🇳

Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

Phase 1
Conditions
Advanced Solid Cancer
Interventions
Drug: SHR-A1904
First Posted Date
2021-05-07
Last Posted Date
2021-10-04
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
94
Registration Number
NCT04877717
Locations
🇨🇳

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: SHR-1819
Drug: Placebo
First Posted Date
2021-02-26
Last Posted Date
2022-11-29
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Target Recruit Count
52
Registration Number
NCT04772365
Locations
🇨🇳

The Third Xiangya Hospital of Central South University, Changsha, Changsha, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy